Track the BillionToOne, Inc. share price and the full directors' dealings record of the company, a listed equity based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Market capitalisation: €4.5bn. The latest transaction was disclosed on 28 August 2026 (J). Among the most active insiders: Atay Oguzhan. Every trade is accessible without an account.
320
Insider Decl.
n/a
Thresholds
€2m
7 ops.
Buy Volume
€20m
119 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate BillionToOne, Inc. Buy (bullish), based on 7 analysts. Average price target: US$119.71.
19Σ signal
Buys €2m€20m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 18,725 of 29,062 companies
42.7
score / 100
Value
37
Quality
49
FCF yld0.4%
Earn yld0.1%
EV/EBITDA·
ROE11%
Gross mgn68%
Net mgn1.0%
Debt/EBITDA5.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
10,000 shares@ US$92.860.020% mcap13.4% of flowClass ASEC144:0001959173-26-005805
25 of 320 declarations
Acerca de BillionToOne, Inc.
BillionToOne, Inc. es una empresa centrada en el desarrollo de tecnologías de diagnóstico molecular. Se especializa en soluciones innovadoras para la detección temprana de enfermedades genéticas.